Get started
Author

Padmasini Kumar

Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo
2001 · Bali Pulendran, Padmasini Kumar, et al. · The Journal of Immunology · 490
PDF
Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer
2006 · John Nemunaitis, Robert O. Dillman, et al. · Journal of Clinical Oncology · 369
PDF
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
2011 · Neil Senzer, Minal Barve, et al. · Molecular Therapy · 201
PDF
Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
2009 · J Nemunaitis, M Nemunaitis, et al. · Cancer Gene Therapy · 154
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
2016 · Jonathan Oh, Minal Barve, et al. · Gynecologic Oncology · 94
CAP37, a Novel Inflammatory Mediator
2002 · Taunia D. Lee, Melva L. Gonzalez, et al. · American Journal Of Pathology · 61
PDF
Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease
1996 · H. Anne Pereira, Padmasini Kumar, et al. · Neurobiology of Aging · 61
CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers
2003 · Taunia D Lee, Melva L Gonzalez, et al. · Microvascular Research · 59
Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
2011 · Jairo Olivares, Padmasini Kumar, et al. · Clinical Cancer Research · 58
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
2015 · Maurizio Ghisoli, Minal Barve, et al. · Molecular Therapy · 55
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
2016 · Donald D. Rao, Christopher Jay, et al. · Molecular Therapy · 50
Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
2014 · John Nemunaitis, Minal Barve, et al. · Oncology · 50
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference
2010 · D D Rao, P B Maples, et al. · Cancer Gene Therapy · 49
Activation of microglia: A neuroinflammatory role for CAP37
2002 · H. Anne Pereira, Xin Ruan, et al. · Glia · 42
PDF
In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
2011 · Anagha P. Phadke, Chris M. Jay, et al. · DNA and Cell Biology · 40
Corneal expression of the inflammatory mediator CAP37.
2002 · Xin Ruan, James Chodosh, et al. · PubMed · 38
FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin
2010 · Phillip Maples, Padmasini Kumar, et al. · BioProcessing Journal · 32
PDF
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform
2014 · J Wu, S Liu, et al. · Cancer Gene Therapy · 24
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
2015 · Minal Barve, Zhaohui Wang, et al. · Molecular Therapy · 22
Functional modulation of smooth muscle cells by the inflammatory mediator CAP37
2004 · Melva L Gonzalez, Xin Ruan, et al. · Microvascular Research · 20
Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application
2012 · Donald D. Rao, Neil Senzer, et al. · Methods in molecular biology · 19
Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
2016 · Minal Barve, Joseph Kuhn, et al. · Biomedical Genetics and Genomics · 12
PDF
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery
2016 · Zhaohui Wang, Christopher M. Jay, et al. · Toxicological Sciences · 11
Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine
2013 · C M Jay, C Ruoff, et al. · Cancer Gene Therapy · 9
Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
2013 · J Nemunaitis, N Senzer, et al. · Gene Therapy · 7
Works count: 32
Citation count: 2,044
H-index: 20
I10-index: 23
Year
Topic
Type